ENHANCING THE BIOAVAILABILITY OF WITHANIA SOMNIFERA: STRATEGIES, CHALLENGES, AND CLINICAL PERSPECTIVES

Withania somnifera, commonly known as “Ashwagandha” or “Indian ginseng” is an essential therapeutic plant of Indian subcontinent regions. It is used in Ayurvedic and indigenous systems of medicine for more than 3,000 years. Withania somnifera indicate various biological actions such as anti-cancer, anti-inflammatory, anti-diabetic, anti-microbial, anti-arthritic, anti-stress/adaptogenic, neuro-protective, cardio-protective, hepato-protective, immunomodulatory properties. These therapeutic effect due to a diverse group of bioactive compounds, particularly withanolides, withaferin-A, withanone, sitoindosides, and alkaloids. But unfortunately, there is the oral bioavailability of these constituents remains a major limitation for clinical efficacy. Many factors responsible for poor bioavailability including low aqueous solubility, poor permeability, extensive first-pass metabolism, and rapid systemic clearance. Accordingly, to overcome these issues, numerous strategies have been proposed and are investigated in this article, such as advanced formulation techniques (nanoemulsions, liposomes, solid lipid nanoparticles, and phytosomes), co-administration with natural bioenhancers like Piperine and curcumin Recent pharmacokinetic studies in both animal models and humans indicate that such approaches significantly improve absorption, half-life, and overall systemic exposure of active constituents However, variability in extract composition, limited clinical trials, and concerns regarding long-term safety of enhanced formulations remain important challenges. Overall, improving the oral bioavailability of W. somnifera constituents holds strong potential to translate its traditional use into consistent therapeutic outcomes, but further well-designed human studies are required to validate these advances. Keywords: Withania Somnifera, Oral Bioavailability, Withanolides, Bioenhancers, Nano-Formulations, Pharmacokinetics